TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03362853
Drug: Moxifloxacin 400Mg Tablet
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive a single dose in a fasting state
Study: NCT01121536
Drug: Armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Armodafinil tablets, taken orally, once daily in the morning
Study: NCT03362853
Drug: Nemonoxacin 750Mg Capsule
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose in a fasting state
Study: NCT01918852
Drug: Teysuno
Normalized name: Teysuno
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01918852
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04768491
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
Study: NCT00003541
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00475878
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg escitalopram/day for 3 months
Study: NCT00096993
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine was provided as a solution for infusion.
Study: NCT00096993
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab was provided as a single-use formulation for infusion.
Study: NCT02865811
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Please see Arms for description.
Study: NCT03787680
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
Study: NCT00003541
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003541
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01540084
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
Study: NCT00003541
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003541
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00022880
Drug: Iodine-131 Anti-B1 Antibody
Normalized name: Iodine-131 anti-b1 antibody
DrugBank: Tositumomab I-131 (DB17991)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00331799
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
Study: NCT04591457
Drug: Insulin Glargine Sansulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
Study: NCT00319670
Drug: MiraLax
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00357747
Drug: AEG35156
Normalized name: AEG35156
DrugBank: AEG35156 (DB06184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
Study: NCT00357747
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
Study: NCT00473512
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
Study: NCT00473512
Drug: Abiraterone acetate MTD
Normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate MTD orally for 12 cycles (28 day each).
Study: NCT00473512
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
Study: NCT04591457
Drug: Insulin Glargine Pen Injector [Lantus]
Normalized name: insulin glargine Pen Injector [Lantus]
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (Lantus) once daily at individually adjusted dose
Study: NCT01411176
Drug: Menthol
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL NPO-11 in a prefilled plastic syringe
Study: NCT02665806
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal ciclesonide spray 200 µg once daily
Study: NCT02665806
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone propionate aqueous nasal spray 200 µg twice a day
Study: NCT00203788
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
Study: NCT03236818
Drug: ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
Study: NCT03245190
Drug: Chiauranib
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg, orally once daily
Study: NCT04065581
Drug: Acarbose/Metformin FDC(BAY81-9783)
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose: 50 mg acarbose/500 mg metformin tablet, oral
Study: NCT04065581
Drug: Glucobay
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose: 50 mg tablet, oral
Study: NCT04065581
Drug: Glucophage
Normalized name: Glucophage
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose: 500 mg tablet, oral
Study: NCT03761225
Drug: Masitinib
Normalized name: masitinib
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03761225
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03761225
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03172897
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
Study: NCT03172897
Drug: Placebo (normal saline)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
Study: NCT00026078
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00026078
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02454634
Drug: IDH1 peptide vaccine
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01192724
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg BID, for 3 months
Study: NCT01192724
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100 mg QD, for 1 year
Study: NCT01192724
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg QD, for 1 year
Study: NCT00208234
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.016 mg/kg IgE
Study: NCT00208234
Drug: Placebo for Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo
Study: NCT00208234
Drug: omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody against IgE. 0.016 mg/kg IgE
Study: NCT00128908
Drug: Standard Continuous Highly Active Antiretroviral Therapy (HAART)
Normalized name: Activated natural killer cell therapy
DrugBank: Activated natural killer cell therapy (DB17172)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00507832
Drug: Pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily topical
Study: NCT00507832
Drug: Pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical application as a cream twice daily
Study: NCT00938587
Drug: PF-04171327 25 mg
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PF-04171327 25 mg tablet every day for 14 days
Study: NCT00938587
Drug: Prednisone 5 mg
Normalized name: prednisone 5 MG
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 5 mg tablet every day for 14 days
Study: NCT03274752
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
Study: NCT01678599
Drug: Benznidazole
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
Study: NCT03464942
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
Study: NCT01010399
Drug: fosamprenavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
Study: NCT01600599
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous 1g and topical 1g
Study: NCT01600599
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mls of topical saline
Study: NCT01912352
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03326752
Drug: DV281
Normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
Study: NCT03326752
Drug: Approved Anti-PD-1 Inhibitor
Normalized name: anti-inhibitor coagulant complex 1 UNT
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved Anti-PD-1 Inhibitor
Study: NCT00306787
Drug: Famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir 500 mg tablet
Study: NCT00306787
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir 500 mg capsule
Study: NCT00306787
Drug: Placebo matching famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
Study: NCT00306787
Drug: Placebo matching valacyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
Study: NCT04129775
Drug: OTO-413
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)
Study: NCT01088347
Drug: mapatumumab
Normalized name: Mapatumumab
DrugBank: Mapatumumab (DB18945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
Study: NCT01088347
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
Study: NCT03085771
Drug: desferal
Normalized name: Desferal
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
Study: NCT00049751
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02630927
Drug: AG-519
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG519 will be tested.
Study: NCT01687387
Drug: Placebo (normal saline solution)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 4 weeks
Study: NCT01064180
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol Tablets 25 mg
Study: NCT00062270
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00062270
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00062270
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00062270
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01358175
Drug: Secukinumab (75 mg)
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab (75 mg)
Study: NCT01358175
Drug: Secukinumab (150 mg)
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab (150 mg)
Study: NCT01715142
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
Study: NCT01715142
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
Study: NCT01526876
Drug: clevidipine butyrate
Normalized name: Clevidipine Butyrate
DrugBank: Clevidipine (DB04920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
Study: NCT01438814
Drug: metformin placebo
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin placebo tablets 500mg
Study: NCT01438814
Drug: linagliptin placebo
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin placebo tablets 5mg
Study: NCT01438814
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin tablets 500mg
Study: NCT01438814
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin tablets 500 mg
Study: NCT01438814
Drug: linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin tablets 5mg
Study: NCT00336323
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
Study: NCT00336323
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
Study: NCT00336323
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
Study: NCT00336323
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
Study: NCT03017521
Drug: TAS-117
Normalized name: TAS-117
DrugBank: TAS-117 (DB15054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-117 16mg, daily
Study: NCT02548923
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparison to propofol
Study: NCT01044758
Drug: Levetiracetam 62.5mg
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 62.5mg twice daily (2 weeks)
Study: NCT01044758
Drug: Levetiracetam 125mg
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 125mg twice daily (2 weeks)
Study: NCT01044758
Drug: Levetiracetam 250mg
Normalized name: LEVETIRACETAM 250MG TAB
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250mg twice daily (2 weeks)
Study: NCT00203463
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04122755
Drug: ALA-1000
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
Study: NCT04122755
Drug: buprenorphine sublingual film
Normalized name: buprenorphine / naloxone Sublingual Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
Study: NCT00469495
Drug: meglumine antimony
Normalized name: meglumine antimoniate
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01375634
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg intravenous over 2 minutes For patients \>60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
Study: NCT03727295
Drug: Idebenone/placebo
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
Study: NCT01072981
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2/day once a week for 3 weeks
Study: NCT04116541
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
Study: NCT04116541
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib, 60 mg /day, continuous, Per os
Study: NCT04116541
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib, 600mg twice daily, Per os
Study: NCT04116541
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os